Tigecycline: A review of properties, applications, and analytical methods

Therapeutic Drug Monitoring

Volumn 32, Issue 3, 2010, Pages 282-288

  Magalhães Da Silva, Lucélia ^a   Salgado, Hérida Regina Nunes ^a,b  

^a Postgraduate Program in Pharmaceutical Sciences   (United States)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Analytical methods; Broadspectrumantibiotic; Glycylcycline; Tigecycline

Indexed keywords

AMIKACIN; AZITHROMYCIN; AZTREONAM; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; HABEKACIN; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIOSTASIS; BINDING AFFINITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ANTAGONISM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION COMPLICATION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN INFECTION; STEADY STATE; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; TETRACYCLINES;

EID: 77952954558     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181dda54f     Document Type: Conference Paper

References (51)

1. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000;6:460-463.
2. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother. 2001;45:1721-1729.
3. Garrison MW, Neumiller JJ, Setter SM. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant Gram-positive organisms. Clin Ther. 2005;27:12-22.
4. Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis. 2006;42(Suppl 4): 164-172.
5. Johnson AP, Livermore DM, Tillotson GS. Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated? J Hosp Infect. 2001;49(Suppl A):S3-S11.
6. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest. 2001;119:S397-S404.
7. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004;10:S122-S129.
8. Bhattacharya M, Parakh A, Narang M. Tigecycline. J Postgrad Med. 2009;55:65-68.
9. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol. 2001;1:464-469.
10. 14C] tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos. 2007;35:1543-1553.
11. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis. 2005;41(Suppl 5): S315-S332.
12. Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobial: a review of in vitro, animal and case report studies. Int J Antimicrob Agents. 2009;34:8.e1-8.e9.
13. Doan T, Fung HB, Mehta D, et al. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther. 2006;28:1079-1106.
14. 2+ cleavage of 16S rRNA. J Antimicrob Chemother. 2004;53: 592-599.
15. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64:63-88.
16. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother. 2005;56:611-614.
17. Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56:470-480.
18. Pakyz AL, Macdougall C, Oinonon M, et al. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med. 2008;168: 2254-2260.
19. Bergeron J, Ammirati M, Danley D. Glycylcyclines bind to the high affinity tetracycline ribosomal binding site and evade Tet (M)-and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother. 1996;40: 2226-2228.
20. Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracyclines efflux pump inhibitors. Drug Resist Updat. 2002;5: 119-125.
21. Townsend ML, Pound MW, Drew RH. Tigecycline: a new glycylcycline antimicrobial. Int J Clin Pract. 2006;60:1662-1672.
22. Kasbekar N. Tigecycline: a new glycylcycline antimicrobial agent. Am J Health Syst Pharm. 2006;63:1235-1243.
23. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58:1221-1229.
24. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother. 2005;49:1629-1632.
25. Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005;41(Suppl 5): S333-S340.
26. Meagher AK, Ambrose PG, Grasela TH, et al. Pharmacokinetic/ pharmacodynamic profile for tigecycline\a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005;52:165-171.
27. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother. 2008;62(Suppl 1):i11-i16.
28. Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther. 2004;26:704-714.
29. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis. 2000;36:19-36.
30. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against Gram positive bacteria. Antimicrob Agents Chemother. 2000;44:2225-2229.
31. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lacta-mases. Diagn Microbiol Infect Dis. 2001;40:173-177.
32. Bradford PA, Petersen PJ, Young M, et al. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent Oxyrase to standardize the test method. Antimicrob Agents Chemother. 2005;49:3903-3909.
33. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006; 43:518-524.
34. Noskin GA. Tigecycline a new glycylcycline for treatment of serious infections. Clin Infect Dis. 2005;41(Suppl 5):S303-S314.
35. Patel R, Rouse MS, Piper KE, et al. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Micro-biol Infect Dis. 2000;38:177-179.
36. Pillar CM, Draghi DC, Dowzicky MJ, et al. In vitro activity of tigecycline against Gram-positive and Gram-negative pathogens as evaluated by broth microdilution and etest. J Clin Microbiol. 2008;46:2862-2867.
37. Petersen PJ, Labthavikul P, Jones CH, et al. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother. 2006;57:573-576.
38. Laplante KL, Rybak MJ, Leuthner KD, et al. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Antimicrob Agents Chemother. 2006;50:1298-1303.
39. Wilcox MH. The tide of antimicrobial resistance and selection. Int J Antimicrob Agents. 2009;34(Suppl 3):S6-S10.
40. Breedt J, Teras J, Gardoviskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005;49:4658-4666.
41. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005;9:251-261.
42. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41(Suppl 5):S341-S353. (Pubitemid 41170381)
43. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg. 2005;3:35-47.
44. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis. 2005;5:88.
45. Nováková L, Sant́?nskú D, Solich P. HPLC methods for the determination of simvastatin and atorvastatin. Trends Analyt Chem. 2008;27:352-367.
46. Rao RN, Meena S, Rao AR. An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices. J Pharm Biomed Anal. 2005;39:349-363.
47. Li C, Sutherland CA, Nightingale CH, et al. Quantitation of tigecycline, a novel glycylcycline, by liquid chromatography. J Chromatogr B. 2004; 811:225-229.
48. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005;49:220-229. (Pubitemid 40065796)
49. Conte Jr JE, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25:523-529.
50. Ji AJ, Saunders JP, Wadgaonkar ND, et al. A novel antibiotic bone assay by liquid chromatography/tandem mass spectrometry for quantitation of tigecycline in rat bone. J Pharm Biomed Anal. 2007;44:970-979.
51. Ji AJ, Saunders JP, Amorusi P, et al. A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS. J Pharm Biomed Anal. 2008;48:866-875.